The usefulness of artificial cerebrospinal fluid in recurrence of chronic subdural hematoma
Not Applicable
- Conditions
- Chronic subdural hematoma
- Registration Number
- JPRN-UMIN000010359
- Lead Sponsor
- wajima City Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients within 14 days after head injury 2. Patients previous received ipsilateral head surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence rate within 3 months after surgery
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie artificial cerebrospinal fluid's effect on chronic subdural hematoma recurrence?
How does artificial cerebrospinal fluid compare to standard burr hole drainage in preventing CSDH recurrence outcomes?
Are there specific biomarkers that predict response to aCSF therapy in chronic subdural hematoma patients?
What adverse events are associated with artificial cerebrospinal fluid administration in JPRN-UMIN000010359 trial?
What combination therapies or neuroprotective agents synergize with aCSF for chronic subdural hematoma treatment?